|
2024
|
Invention
|
Clec9a-based chimeric protein formulations. The present application provides, in part, pharmaceut... |
|
|
Invention
|
Clec9a binding agents and use thereof.
The present invention relates, in part, to agents that bi... |
|
|
Invention
|
Sirp1a targeted chimeric proteins and uses thereof.
The present invention relates, in part, to a... |
|
2023
|
Invention
|
Therapeutic targeting of non-cellular structures.
The present invention relates, in part, to chi... |
|
|
Invention
|
Bi-functional chimeric proteins and uses thereof.
The present invention relates, in part, to tar... |
|
|
Invention
|
Targeted therapeutic agents and uses thereof.
The present invention relates, in part, to chimeri... |
|
|
Invention
|
Il-2 trap molecules. The present disclosure provides methods of reducing, mitigating, or eliminat... |
|
2022
|
Invention
|
Cd8 binding agents.
The present invention relates, in part, to agents that bind CD8 and their us... |
|
|
Invention
|
Pd-1 and pd-l1 binding agents.
The present invention relates, in part, to agents that bind PD-1 ... |
|
|
Invention
|
Split human ifn-gamma and tnf-alpha constructs and uses thereof.
The present invention relates, ... |
|
|
Invention
|
Split human ifn-gamma and tnf-alpha constructs and uses thereof. The present invention relates, i... |
|
|
Invention
|
Therapeutic interferon alpha 1 proteins.
The present invention relates, in part, to chimeric pro... |
|
|
Invention
|
Interleukin-1 alpha chimeric protein.
The present invention relates, in part, to chimeric protei... |
|
|
Invention
|
Interleukin-1 alpha chimeric protein. The present invention relates, in part, to chimeric protein... |
|
|
Invention
|
Targeted chimeric proteins and uses thereof.
The present invention relates, in part, to chimeric... |
|
|
Invention
|
Il-2 based constructs.
The present invention relates, in part, to chimeric proteins or chimeric ... |
|
|
Invention
|
Il-2 based constructs. The present invention relates, in part, to chimeric proteins or chimeric p... |
|
2021
|
Invention
|
Targeted mutant interferon-beta and uses thereof.
The present invention relates, in part, to chi... |
|
|
Invention
|
Targeted mutant interferon-gamma and uses thereof.
The present invention relates, in part, to ch... |
|
|
Invention
|
Clec9a binding agents.
The present invention relates, in part, to agents that bind Clec9A and th... |
|
2020
|
Invention
|
Targeted engineered interferon and uses thereof.
The present invention relates, in part, to chim... |
|
|
Invention
|
Bispecific signaling agents and uses thereof.
The present invention relates, in part, to bispeci... |
|
|
Invention
|
Detection of novel degradation-related interactions.
The present invention is related to a metho... |
|
|
Invention
|
Detection of novel degradation-related interactions. The present invention is related to a method... |
|
|
Invention
|
Detection of molecular interactions.
Methods for detection of molecular interactions, such as pr... |
|
|
Invention
|
Modulation of protein degradation.
Methods of assessing the efficacy of an agent in treating a d... |
|
|
Invention
|
Modulation of protein degradation. Methods of assessing the efficacy of an agent in treating a di... |
|
|
Invention
|
Detection of molecular interactions. Methods for detection of molecular interactions, such as pro... |
|
|
Invention
|
Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes.
The pres... |
|
|
Invention
|
Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes. The prese... |
|
|
Invention
|
Fibroblast activation protein binding agents and use thereof.
The present invention relates, in ... |
|
|
Invention
|
Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3).
... |
|
|
Invention
|
Clec9a-based chimeric protein complexes.
The present invention relates, in part, to chimeric pro... |
|
|
Invention
|
Therapeutic interferon alpha 1 proteins. The present invention relates, in part, to chimeric prot... |
|
|
Invention
|
Fibroblast activation protein binding agents and use thereof. The present invention relates, in p... |
|
|
Invention
|
Clec9a-based chimeric protein complexes. The present invention relates, in part, to chimeric prot... |
|
2019
|
Invention
|
Modulation of dendritic cell lineages.
The present invention relates, in part, to agents, chimer... |
|
|
Invention
|
Sirp1α targeted chimeric proteins and uses thereof. The present invention relates, in part, to ag... |
|
|
Invention
|
Bi-functional proteins and construction thereof.
The present invention relates, in part, to Fc-b... |
|
2018
|
Invention
|
Clec9a binding agents comprising a recombinant heavy-chain only antibody (vhh). The present inven... |
|
|
Invention
|
Pd-1 and pd-l1 binding agents. The present invention relates, in part, to agents that bind PD-1 o... |
|
2017
|
Invention
|
Therapeutic targeting of non-cellular structures. The present invention relates, in part, to chim... |
|
|
Invention
|
Chimeric protein comprising an interferon alpha 2mutant and a pd-l1 binding moiety. The present i... |
